ESMO Congress 2021: highlights from the EORTC gastrointestinal
tract cancer group's perspective

J 2022

ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective

KOESSLER, T., M. ALSINA, D. ARNOLD, I. BEN-AHARON, M. COLLIENNE et. al.

Základní údaje

Originální název

ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective

Autoři

KOESSLER, T. (garant), M. ALSINA, D. ARNOLD, I. BEN-AHARON, M. COLLIENNE, M. P. LUTZ, C. NEUZILLET, Radka OBERMANNOVÁ (203 Česká republika, domácí), M. PEETERS, F. SCLAFANI, E. SMYTH, J. W. VALLE, A. D. WAGNER, L. WYRWICZ, E. FONTANA a M. MOEHLER

Vydání

ESMO OPEN, AMSTERDAM, ELSEVIER, 2022, 2059-7029

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 7.300

Kód RIV

RIV/00216224:14110/22:00128331

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.esmoop.2022.100392

UT WoS

000819921700001

Klíčová slova anglicky

oesophagus cancer; stomach cancer; pancreatic cancer; neuroendocrine tumours; colorectal cancer

Štítky

14110516, 14110811, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 27. 1. 2023 13:58, Mgr. Tereza Miškechová

Anotace

V originále

There has been no major change of practice in gastrointestinal oncology at the European Society for Medical Oncology (ESMO) symposium 2021, but confirmation that immunotherapy in combination with chemotherapy has become standard of care in several indications. The European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Track Cancer Group has selected important phase II and III trials presented during the symposium across all gastrointestinal cancers as well as early reports on new drugs or new combinations that may change practice in the future.

Citovat

KOESSLER, T., M. ALSINA, D. ARNOLD, I. BEN-AHARON, M. COLLIENNE, M. P. LUTZ, C. NEUZILLET, Radka OBERMANNOVÁ, M. PEETERS, F. SCLAFANI, E. SMYTH, J. W. VALLE, A. D. WAGNER, L. WYRWICZ, E. FONTANA a M. MOEHLER. ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective. ESMO OPEN. AMSTERDAM: ELSEVIER, 2022, roč. 7, č. 2, s. 1-8. ISSN 2059-7029. Dostupné z: https://dx.doi.org/10.1016/j.esmoop.2022.100392.

@article{2250084,
   author = {Koessler, T. and Alsina, M. and Arnold, D. and BenandAharon, I. and Collienne, M. and Lutz, M. P. and Neuzillet, C. and Obermannová, Radka and Peeters, M. and Sclafani, F. and Smyth, E. and Valle, J. W. and Wagner, A. D. and Wyrwicz, L. and Fontana, E. and Moehler, M.},
   article_location = {AMSTERDAM},
   article_number = {2},
   doi = {http://dx.doi.org/10.1016/j.esmoop.2022.100392},
   keywords = {oesophagus cancer; stomach cancer; pancreatic cancer; neuroendocrine tumours; colorectal cancer},
   language = {eng},
   issn = {2059-7029},
   journal = {ESMO OPEN},
   title = {ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective},
   url = {https://www.sciencedirect.com/science/article/pii/S2059702922000126?via%3Dihub},
   volume = {7},
   year = {2022}
}

TY  - JOUR
ID  - 2250084
AU  - Koessler, T. - Alsina, M. - Arnold, D. - Ben-Aharon, I. - Collienne, M. - Lutz, M. P. - Neuzillet, C. - Obermannová, Radka - Peeters, M. - Sclafani, F. - Smyth, E. - Valle, J. W. - Wagner, A. D. - Wyrwicz, L. - Fontana, E. - Moehler, M.
PY  - 2022
TI  - ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective
JF  - ESMO OPEN
VL  - 7
IS  - 2
SP  - 1-8
EP  - 1-8
PB  - ELSEVIER
SN  - 20597029
KW  - oesophagus cancer
KW  - stomach cancer
KW  - pancreatic cancer
KW  - neuroendocrine tumours
KW  - colorectal cancer
UR  - https://www.sciencedirect.com/science/article/pii/S2059702922000126?via%3Dihub
N2  - There has been no major change of practice in gastrointestinal oncology at the European Society for Medical Oncology (ESMO) symposium 2021, but confirmation that immunotherapy in combination with chemotherapy has become standard of care in several indications. The European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Track Cancer Group has selected important phase II and III trials presented during the symposium across all gastrointestinal cancers as well as early reports on new drugs or new combinations that may change practice in the future.
ER  -

KOESSLER, T., M. ALSINA, D. ARNOLD, I. BEN-AHARON, M. COLLIENNE, M. P. LUTZ, C. NEUZILLET, Radka OBERMANNOVÁ, M. PEETERS, F. SCLAFANI, E. SMYTH, J. W. VALLE, A. D. WAGNER, L. WYRWICZ, E. FONTANA a M. MOEHLER. ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective. \textit{ESMO OPEN}. AMSTERDAM: ELSEVIER, 2022, roč.~7, č.~2, s.~1-8. ISSN~2059-7029. Dostupné z: https://dx.doi.org/10.1016/j.esmoop.2022.100392.

Podrobný výpis o publikaci